NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020-Reference-Cited by-同舟云学术

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

Published:2020-03 Issue:3 Volume:18 Page:230-241
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Thompson John A.¹,Schneider Bryan J.²,Brahmer Julie³,Andrews Stephanie⁴,Armand Philippe⁵,Bhatia Shailender¹,Budde Lihua E.⁶,Costa Luciano⁷,Davies Marianne⁸,Dunnington David⁹,Ernstoff Marc S.¹⁰,Frigault Matthew¹¹,Kaffenberger Benjamin H.¹²,Lunning Matthew¹³,McGettigan Suzanne¹⁴,McPherson Jordan¹⁵,Mohindra Nisha A.¹⁶,Naidoo Jarushka³,Olszanski Anthony J.¹⁷,Oluwole Olalekan¹⁸,Patel Sandip P.¹⁹,Pennell Nathan²⁰,Reddy Sunil²¹,Ryder Mabel²²,Santomasso Bianca²³,Shofer Scott²⁴,Sosman Jeffrey A.¹⁶,Wang Yinghong²⁵,Weight Ryan M.²⁶,Johnson-Chilla Alyse²⁷,Zuccarino-Catania Griselda²⁷,Engh Anita²⁷

Affiliation:

1. 1Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

2. 2University of Michigan Rogel Cancer Center;

3. 3The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

4. 4Moffitt Cancer Center;

5. 5Dana-Farber/Brigham and Women’s Cancer Center;

6. 6City of Hope National Medical Center;

7. 7O’Neal Comprehensive Cancer Center at UAB;

8. 8Yale Cancer Center/Smilow Cancer Hospital;

9. 9Patient Advocate;

10. 10Roswell Park Comprehensive Cancer Center;

11. 11Massachusetts General Hospital Cancer Center;

12. 12The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

13. 13Fred & Pamela Buffett Cancer Center;

14. 14Abramson Cancer Center at the University of Pennsylvania;

15. 15Huntsman Cancer Institute at the University of Utah;

16. 16Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

17. 17Fox Chase Cancer Center;

18. 18Vanderbilt-Ingram Cancer Center;

19. 19UC San Diego Moores Cancer Center;

20. 20Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

21. 21Stanford Cancer Institute;

22. 22Mayo Clinic Cancer Center;

23. 23Memorial Sloan Kettering Cancer Center;

24. 24Duke Cancer Institute;

25. 25The University of Texas MD Anderson Cancer Center;

26. 26University of Colorado Cancer Center; and

27. 27National Comprehensive Cancer Network.

Abstract

The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor–related diarrhea/colitis and cardiovascular irAEs.

Publisher

Harborside Press, LLC

Subject

Oncology

Cited by 270 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology;Genes & Diseases;2024-03

2. Case Report: Temporary pacing using active fixation lead and invasive electrophysiology studies for immune checkpoint inhibitor associated reversible advanced atrioventricular block;Frontiers in Cardiovascular Medicine;2024-02-05

3. The Multidisciplinary Management of Primary Hepatocellular Carcinoma;Gastrointestinal Oncology ‐ A Critical Multidisciplinary Team Approach 2e;2024-01-23

4. Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis;Investigational New Drugs;2024-01-23

5. Development and validation of a nomogram for predicting immune‐related pneumonitis after sintilimab treatment;Cancer Medicine;2024-01-12